In contrast, Eichenauer et al. [137] classified the expression level of CHK2 in prostate cancer into three grades (weak, medium, and strong) through immunohistochemical analysis and found that the high expression of CHK2 was associated with a variety of malignant tumor characteristics and could be used as an independent predictor for the early recurrence of prostate cancer. The gene discussed is CHEK2; the disease is prostate carcinoma.